Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. Separately, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results